SOLID-TIMI 52

SOLID-TIMI 52 was a randomized, double-blind, placebo-controlled trial to assess the efficacy of darapladib, a novel Lp-PLA2 inhibitor, when added to standard of care in high-risk patients stabilized after ACS.

MAIN RESULTS:
Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial

JAMA. 2014 Sep 10;312(10):1006-15.

PRESENTATIONS

TIMI 52 Slides
SOLID Ceramides (Gencer, AHA 2019)
A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients with Cardiometabolic Disease (Patel, AHA 2020)
Clinical Applications of a Polygenic Risk Score to Predict Atrial Fibrillation in Patients with Cardiometabolic Disease (Garfinkel, AHA 2021)
A Genetic Risk Score to Predict Peripheral Artery Disease and Acute Limb Ischemia in Patients With Cardiometabolic Disease (Patel, AHA 2021)
Development of a Novel Polygenic Risk Score to Predict Risk of Aortic Stenosis Events (Small, AHA 2022)
Performance of a Polygenic Risk Score for CAD Across the Spectrum of ASCVD-An Analysis of 60k Patients from 6 TIMI Randomized Trials (Zimerman, AHA 2023)
Polygenic Risk in Heart Failure (Haller, AHA 2024)
Galectin-3 and Cardiovascular and Kidney Outcomes-Individual Patient Data Meta-Analysis of 74,358 Patients From 5 Multinational Clinical Trials (Haller, ACC 2025)

OTHER PUBLICATIONS

Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. Am Heart J. 2011 Oct;162(4):613-619.e1.

Lp-PLA2 Inhibitors for the Reduction of Cardiovascular Events. Cardiol Ther. 2013 Dec; 2(2): 125–134.

Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial. J Am Heart Assoc. 2017 Jan 11;6(1):e004332.

Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials. J Am Coll Cardiol. 2017 Mar 28;69(12):1549-1559. 

Interleukin-6 And The Risk Of Adverse Outcomes In Patients After An Acute Coronary Syndrome: Observations From The SOLID-TIMI 52 Trial. J Am Heart Assoc. 2017 Oct 24;6(10):e005637.

Metabolic syndrome and the risk of adverse cardiovascular events after an acute coronary syndrome. Eur J Prev Cardiol. 2018 May;25(8):830-838.

Metabolic Syndrome And The Risk Of Adverse Cardiovascular Events After An Acute Coronary Syndrome: Insights From SOLID-TIMI 52 Trial. Eur J Prev Cardiol. 2018 May;25(8):830-838.

Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2018 Jun 1;3(6):473-480.

Cystatin C for Risk Stratification in Patients After an Acute Coronary Syndrome. J Am Heart Assoc. 2018 Oct 16;7(20):e009077.

Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. Eur Heart J. 2018 Nov 7;39(42):3810-3820.

Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes. J Am Coll Cardiol. 2019 Dec 17;74(24):3013-3022.

Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome. Eur J Prev Cardiol . 2022 May 6;29(6):895-902.

Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. Circulation. 2021 Feb 16;143(7):685-695.

A polygenic risk score predicts atrial fibrillation in cardiovascular disease. Eur Heart J. 2023 Jan 14;44(3):221-231.

Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis. Eur Heart J. 2023 Jan 21;44(4):293-300.

Novel Polygenic Risk Score and Established Clinical Risk Factors for Risk Estimation of Aortic Stenosis. JAMA Cardiol. 2024 Apr 1;9(4):357-366.

A Polygenic Risk Score to Predict Incident Heart Failure Across the Spectrum of Cardiovascular Risk. J Am Coll Cardiol. 2025 2025 Sep 23;86(12):860-873.

Statistical approaches for systematically missing covariates in individual participant data meta-analysis: insights and applications using 5 large cardiovascular trials. Am J Epidemiol. 2025 Oct 9:kwaf226. doi: 10.1093/aje/kwaf226.

Polygenic Risk Score for Coronary Artery Disease Across the Spectrum of Atherosclerotic Disease. Eur J Prev Cardiol. 2025 Oct 28:zwaf693. doi: 10.1093/eurjpc/zwaf693. 

A polygenic risk score for peripheral artery disease and major adverse limb events. Eur Heart J. 2025 Nov 28:ehaf891. doi: 10.1093/eurheartj/ehaf891.

Genomic and transcriptomic analyses of aortic stenosis enhance therapeutic target discovery and disease prediction. Nat Genet. 2025 Dec 19. doi: 10.1038/s41588-025-02417-6.